LAI market to reach $24.45 billion by 2030

The long-acting injectables market is projected to grow from $13.31 billion in 2025 to $15.01 billion in 2026, driven by rising schizophrenia and bipolar disorder treatment needs, better adherence, and new delivery technologies. North America led the market in 2025, while Asia-Pacific is forecast to grow fastest through 2030.

Why it matters: - Long-acting injectables can improve medication adherence by reducing how often patients need treatment. - The market's growth reflects rising demand for sustained drug delivery in psychiatry, infectious disease and contraception. - The category is becoming more important as healthcare systems expand homecare, outpatient care and specialty-clinic treatment models.

What happened: - The Business Research Company released its Long-Acting Injectables (LAIs) Global Market Report 2026 – Market Size, Trends, And Forecast 2026-2035. - The report pegs the LAIs market at $13.31 billion in 2025 and $15.01 billion in 2026. - The report forecasts the market will reach $24.45 billion by 2030, implying 13.0% annual growth over the forecast period. - North America held the largest market share in 2025. - Asia-Pacific is forecast to be the fastest-growing regional market.

The details: - Long-acting injectables are medicines designed to release active compounds steadily over weeks or months after a single injection. - The delivery model reduces the need for frequent dosing compared with oral medicines and shorter-acting injectables. - Historical growth has been supported by higher schizophrenia and bipolar disorder prevalence, stronger demand for adherence, early depot injection innovation, wider use of hormonal injectable contraceptives and limited sustained-release alternatives. - Future growth is expected from nano- and polymer-based delivery systems, more approvals for long-acting antivirals, precision medicine adoption, more homecare and outpatient treatment, and investment in extended-release injectable pipelines. - Emerging uses include chronic psychiatric conditions, depot formulations that cut dosing frequency, long-acting antivirals for infectious diseases and broader use in outpatient and specialty clinics. - The regional analysis covers Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa. - The report also includes market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspot infographics, and updated graphics and tables.

Between the lines: - The strongest demand appears to come from conditions where missed doses can drive relapse or poor outcomes, especially schizophrenia. - WebMD LLC reported in January 2026 that schizophrenia created nearly $367 billion in U.S. economic burden in 2024 and affected about 3.1 million adults. - That scale helps explain why developers and providers are pushing drug formats that improve consistency and reduce treatment gaps. - The report's emphasis on outpatient and homecare settings suggests LAIs are moving beyond specialty use into broader care pathways.

What's next: - The market is expected to keep expanding through 2030 as more long-acting antiviral and extended-release products enter development and approvals. - Asia-Pacific's growth will likely depend on healthcare investment, mental health awareness and access to advanced treatments. - The Business Research Company is offering a free sample of the report and access to the full market report through its website.

The bottom line: - LAIs are shifting from a niche delivery method to a broader platform for improving adherence across multiple therapeutic areas, and the market is on track for sustained double-digit growth.